American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
American Journal of Medical Case Reports. 2021, 9(3), 198-200
DOI: 10.12691/ajmcr-9-3-16
Open AccessCase Report

Guillain-Barré Syndrome in a COVID-19 Patient: A Case Report and Review of Management Strategies

Zachary Mostel1, Parinaz Ayat1, Violeta Capric1, Andrea Trimmingham1 and Samy I. McFarlane1,

1Department of Medicine, State University of New York-Downstate, Downstate-Health Science University, Brooklyn, NY 11203

Pub. Date: January 14, 2021

Cite this paper:
Zachary Mostel, Parinaz Ayat, Violeta Capric, Andrea Trimmingham and Samy I. McFarlane. Guillain-Barré Syndrome in a COVID-19 Patient: A Case Report and Review of Management Strategies. American Journal of Medical Case Reports. 2021; 9(3):198-200. doi: 10.12691/ajmcr-9-3-16


Guillain-Barré syndrome (GBS) in an immune mediated disease that affects peripheral nerves with possible life-threatening complications. GBS has multiple subtypes including acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor sensory axonal neuropathy (AMSAN), which can make GBS difficult to diagnose. GBS commonly presents after viral infections such as influenza virus, campylobacter jejuni, and zika virus. GBS commonly presents with a prolonged clinical course leading to increased morbidity among affected patients. It is not surprising that COVID-19 has been connected with multiple cases of GBS, which may alter the recovery course for several patients post-COVID. In this report, we present a case of 69-year-old-female who presented with progressive motor weakness and loss of sensation in her extremities after testing positive for antibodies to COVID-19 one-month prior to presentation. Her presentation and treatment of GBS in the setting of COVID-19 is an example of one of the many COVID-19 complications and sheds light on the prolonged recovery course that we may experience as clinicians in the wake of this pandemic.

COVID-19 Guillain-Barré syndrome SARS-CoV2

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Li X, Zai J, Zhao Q, Nie Q, Li Y, Foley B, et al. Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol. (2020) 92: 602-611.
[2]  Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China. N Engl J Med. (2020) 382: 727-33.
[3]  WHO Director-General's opening remarks at the media briefing on COVID-19 (2020). Available onlineat: opening-remarks-at-the-media-briefing-on-covid-19 (accessed November 24, 2020).
[4]  Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395(10223): 497-506.
[5]  Katyal N, Narula N, Acharya S, Govindarajan R. Neuromuscular complications with sars-cov-2 infection: a review. Front Neurol. (2020) 11: 1052.
[6]  Favas TT, Dev P, Chaurasia RN, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci. (2020)41(12): 3437-3470.
[7]  Yuki N, Hartung H-P. Guillain-Barré syndrome. N Engl J Med. (2012) 366(24): 2294-2304.
[8]  Cao-Lormeau V-M, Blake A, Mons S, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. (2016) 387(10027): 1531-1539.
[9]  Kim JE, Heo JH, Kim HO, et al. Neurological complications during treatment of middle east respiratory syndrome. J Clin Neurol. (2017) 13(3): 227-233.
[10]  Hadden, R. D. et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann. Neurol. (1998) 44, 780-788.
[11]  Willison, H. J., Jacobs, B. C. & van Doorn, P. A. Guillain-Barré syndrome. Lancet (2016) 388, 717-727.
[12]  Leonhard, S.E., Mandarakas, M.R., Gondim, F.A.A. et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. (2019) 15, 671-683.
[13]  Hughes, R. A., Swan, A. V. & van Doorn, P. A. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst. Rev. (2014) 9, CD002063.
[14]  Chevret, S. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst. Rev. (2017) 2, CD001798.
[15]  Verboon, C., van Doorn, P. A. & Jacobs, B. C. Treatment dilemmas in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry (2017) 88, 346-352
[16]  Hasan I, Saif-Ur-Rahman KM, Hayat S, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: A systematic review and individual participant data meta-analysis. J Peripher Nerv Syst. (2020) Dec; 25(4): 335-343.
[17]  Antontio Uncini, Jean-Michel Vallat, Bart C Jacobs. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry. (2020) Oct; 91(10): 1105-1110. Epub 2020 Aug 27.
[18]  Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system. Viruses. (2020) 12: 14.
[19]  Xia H, Lazartigues E. Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem. (2008) 107: 1482-94.
[20]  Erika Scheidl, Daniel Diez Canseco, Aleksandar Hadji-Naumov, Benjamin Bereznai. Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature. J Peripher Nerv Syst. (2020) Jun; 25(2): 204-207. Epub 2020 May 26.